IOncology

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 30 to June 3. At the conference, Professor Ting Li of Fudan University Shanghai Cancer Center delivered a Rapid Oral Abstract presentation on behalf of her team, showcasing a phase II clinical study (Abstract #1018) titled "A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases." Following her presentation, Oncology Frontier conducted an exclusive interview with Professor Li, where she shared insights into the rationale behind the study design, the benefits of the triplet therapy, and the specific patient groups most likely to benefit.

A dynamic understanding of the tumor microenvironment (TME) is essential for uncovering the mechanisms behind treatment response and disease progression. At the 2025 ASCO Annual Meeting, Professor Jieqiong Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented an innovative translational study (Abstract #1022) exploring the efficacy and safety of a novel combination therapy in patients with HER2-positive metastatic breast cancer who had failed second-line or later treatments. The team employed single-cell sequencing to analyze TME changes before and after treatment with KN046, a bispecific anti-CTLA-4/PD-L1 antibody, and KN026, a bispecific anti-HER2 antibody. The results revealed distinct immunological  differences between responders and non-responders and identified the baseline macrophage-to-lymphatic endothelial cell (Mϕ/LEC) ratio as a predictive biomarker of treatment response. This study offers new insights into individualized care strategies for breast cancer.

At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP regimen) as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Results showed a median PFS of 11.8 months and median OS of 27.1 months, with manageable toxicity. The second study, an ongoing trial (Abstract #TPS1122), aims to predict treatment response to T-DXd in HER2-positive breast cancer brain metastases using68Ga-FAPI PET-CT to assess tumor metabolic heterogeneity. The trial is actively recruiting patients.This article specifically introduces two studies.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer, offers an innovative head-to-head comparison between a carboplatin-free THP regimen and the traditional carboplatin-containing TCbHP regimen. The findings revealed that the THP regimen was non-inferior to TCbHP in terms of pathological complete response (pCR), with a significantly better toxicity profile. This important discovery not only provides a new therapeutic option for patients with HER2-positive breast cancer but also reflects a patient-centered approach to treatment—marking a shift toward more precise and individualized care. Following the presentation, Oncology Frontier interviewed Professor Wang to discuss the study’s background, significance, and what the future holds for HER2-positive breast cancer treatment.

Editor’s Note: The 2025 ASCO annual meeting was held from May 30 to June 3 in Chicago, USA. At this annual meeting, a number of research results carried out by…

Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.

In 2025, Dr. Husam Abu Jazar and colleagues at King Hussein Cancer Center published two impactful studies that could shape transplant care moving forward. The first study analyzed outcomes from…

The therapeutic landscape in oncology is undergoing a profound shift with the rise of genome engineering technologies such as CRISPR/Cas9, base editing, and prime editing. These tools are enabling the…

Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and safety outcomes in Chinese patients. Given that nivolumab plus chemotherapy has been approved in over 50 countries as a first-line treatment, this updated evaluation assesses whether its benefits remain sustained over time in this population.